Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
5-fluorouracil + carmustine + cisplatin + cyclophosphamide + doxorubicin
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
This combination is a multi-agent chemotherapy regimen. Each component targets cancer cells differently: - 5-fluorouracil is an antimetabolite that interferes with DNA synthesis. - Carmustine is an alkylating agent that damages DNA. - Cisplatin is a platinum-based drug that cross-links DNA, preventing cell division. - Cyclophosphamide is an alkylating agent that interferes with DNA replication. - Doxorubicin is an anthracycline that intercalates DNA and inhibits topoisomerase II.
02
Targets
DNATS (Thymidylate synthase)TOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on 5-fluorouracil + carmustine + cisplatin + cyclophosphamide + doxorubicin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 5-fluorouracil + carmustine + cisplatin + cyclophosphamide + doxorubicin.